Market Overview

Antares Pharma Given 5-Star Upgrade By Vetr


The Vetr community has upgraded Antares Pharma Inc. (NASDAQ: ATRS) from 4 stars to 5 stars.

The stock has traded up a little under $1 year-to-date with its second-quarter earnings report coming up on August 8.

See how crowdsourced ratings can help predict the market?

Vetr members have given Antares Pharma a Strong Buy rating and a $3.18 price target. This price target is higher than the $3.10 price target from professional analysts. The stock opened Wednesday around $3.18.

Of all Vetr voters, 100 percent believe traders should buy Antares stock while none believe that traders should sell Antares stock.

For Vetr’s full analysis of Antares, go here.

Posted-In: VetrUpgrades Crowdsourcing Analyst Ratings General


Related Articles (ATRS)

View Comments and Join the Discussion!

Latest Ratings

EMNMorgan StanleyUpgrades90.0
DERMRaymond JamesUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Exxon Mobil Downgraded By Vetr Crowd

Big 5 German Automakers Implicated In Price-Fixing Scandal; VW Exec Plans To Cop Plea In Emissions Probe